A phase Ib/IIa trial of panobinostat in combination with trastuzumab in adult female patients with HER2 [human epidermal growth factor receptor 2] positive metastatic breast cancer whose disease has progressed during or following therapy with trastuzumab.

Trial Profile

A phase Ib/IIa trial of panobinostat in combination with trastuzumab in adult female patients with HER2 [human epidermal growth factor receptor 2] positive metastatic breast cancer whose disease has progressed during or following therapy with trastuzumab.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 11 May 2016

At a glance

  • Drugs Panobinostat (Primary) ; Panobinostat (Primary) ; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 04 Apr 2016 Status changed from completed to discontinued due to insufficient evidence of clinical benefit.
    • 24 Mar 2012 Additional location (United Kingdom) added as reported by European Clinical Trials Database record.
    • 24 Mar 2012 This trial is recruiting in (France and United Kingdom) as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top